340 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Amgen's (AMGN) Humira Biosimilar Receives Approval in EU http://www.zacks.com/stock/news/254077/amgens-amgn-humira-biosimilar-receives-approval-in-eu?cid=CS-ZC-FT-254077 Mar 24, 2017 - Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).
Teva Pharma Denies Rumors of Global Workforce Reduction http://www.zacks.com/stock/news/254066/teva-pharma-denies-rumors-of-global-workforce-reduction?cid=CS-ZC-FT-254066 Mar 24, 2017 - According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.
Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK? http://www.zacks.com/stock/news/254783/pharma-stock-roundup-fda-nod-for-sny-roche-drugs-generic-advair-relief-for-gsk?cid=CS-ZC-FT-254783 Mar 31, 2017 - Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
Why Equal Weighted Mutual Funds Scoring Over Index Funds http://www.zacks.com/stock/news/254739/why-equal-weighted-mutual-funds-scoring-over-index-funds?cid=CS-ZC-FT-254739 Mar 30, 2017 - Investors interested in maintaining a diversified portfolio might consider investing in equal-weight funds.
Did Pharma & Biotech M&As Pick Pace in Q1? http://www.zacks.com/stock/news/256645/did-pharma-biotech-mas-pick-pace-in-q1?cid=CS-ZC-FT-256645 Apr 18, 2017 - Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.
Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View http://www.zacks.com/stock/news/259943/allergan-agn-beats-q1-earnings-estimates-ups-2017-view?cid=CS-ZC-FT-259943 May 09, 2017 - Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.
Allergan (AGN) Beats Q1 Earnings & Sales; Ups 2017 View http://www.zacks.com/stock/news/259833/allergan-agn-beats-q1-earnings-sales-ups-2017-view?cid=CS-ZC-FT-259833 May 09, 2017 - Allergan???s first-quarter earnings of $3.35 per share were above our consensus estimate of $3.32 per share.
Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan http://www.zacks.com/stock/news/260286/impax-ipxl-q1-earnings-miss-stock-up-on-cost-savings-plan?cid=CS-ZC-FT-260286 May 11, 2017 - Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period
Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls http://www.zacks.com/stock/news/260350/teva-teva-q1-earnings-in-line-sales-lag-as-copaxone-falls?cid=CS-ZC-FT-260350 May 12, 2017 - Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.
Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss http://www.zacks.com/stock/news/260909/cardiome-crme-q1-loss-wider-than-expected-sales-miss?cid=CS-ZC-FT-260909 May 17, 2017 - Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents.

Pages: 12345678910...34

<<<Page 5>